GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verve Therapeutics Inc (NAS:VERV) » Definitions » Cyclically Adjusted Book per Share

Verve Therapeutics (Verve Therapeutics) Cyclically Adjusted Book per Share : $0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verve Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Verve Therapeutics's adjusted book value per share data for the fiscal year that ended in Dec. 2023 was $7.314. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-17), Verve Therapeutics's current stock price is $ 5.98. Verve Therapeutics's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec. 2023 was $0.00. Verve Therapeutics's Cyclically Adjusted PB Ratio of today is .


Verve Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Verve Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verve Therapeutics Cyclically Adjusted Book per Share Chart

Verve Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
- - - - -

Verve Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Verve Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Verve Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verve Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verve Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Verve Therapeutics's Cyclically Adjusted PB Ratio falls into.



Verve Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Verve Therapeutics's adjusted Book Value per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_Book=Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=7.314/129.4194*129.4194
=7.314

Current CPI (Dec. 2023) = 129.4194.

Verve Therapeutics does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate it.


Verve Therapeutics  (NAS:VERV) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Verve Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Verve Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Verve Therapeutics (Verve Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
201 Brookline Avenue, Suite 601, Boston, MA, USA, 02215
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Executives
Krishna Yeshwant director, 10 percent owner C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Allison Dorval officer: Chief Financial Officer C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Fred T. Fiedorek officer: Chief Medical Officer 55 BALDWIN LANE, PRINCETON NJ 08540
Joan Nickerson officer: Chief Administrative Officer C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215
Andrew Bellinger officer: Chief Scientific Officer 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Gv 2017 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc. other: Member of 10% Group 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Sekar Kathiresan director, 10 percent owner, officer: Chief Executive Officer 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Lonnel Coats director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
Alexander Cumbo director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Burt A Adelman director, 10 percent owner DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Andrew D. Ashe officer: See Remarks C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Logos Global Management Lp 10 percent owner 1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116

Verve Therapeutics (Verve Therapeutics) Headlines

From GuruFocus